Abstract: The present document describes techniques for a magnetically self-shielded speaker box for a mobile device. The speaker box described herein includes a thin metal enclosure, thereby reducing or eliminating plastic components from the exterior enclosure of the speaker box. The metal of the enclosure has a high magnetic permeability to prevent penetration of a magnetic field generated by the speaker transducer within the exterior enclosure. Also, the exterior enclosure includes at least two enclosure portions that are joined together with a continuous welded seam. Accordingly, the speaker box described herein is a thin-walled, fully metal, high-permeability enclosure resulting in a smaller, self-shielded solution that reduces both (i) the total physical volume of the speaker box for a given internal speaker back volume and (ii) the spacing requirements to adjacent voice-coil-motor auto-focus camera modules.

Abstract: The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g.

Abstract: The present invention relates to an organic compound, and an electronic element and an electronic apparatus using same. The organic compound has a structure represented by a formula (I). The organic compound is applied to an organic electroluminescent device, and can significantly improve the performance of the device.

Abstract: Provided are a mutant HPPD polypeptide having high resistance to a herbicide and an encoding gene thereof, and an application thereof in an improved plant. The amino acid at position 282 of the mutant HPPD polypeptide is mutated from arginine to serine at a wild-type HPPD polypeptide. In addition, the mutant HPPD polypeptide further comprises an amino acid at position 349 that is mutated from glutamic acid to lysine, and/or an amino acid at position 156 that is mutated from alanine to valine. The mutated HPPD polypeptide can be used for cultivating plants having resistance to a herbicide having HPPD inhibition.

Abstract: Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) CCR8, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD94 and/or NKG2A, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL1B and/or IL1A, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complex, and methods of use thereof.

Abstract: This disclosure relates to genetically modified immunodeficient animals which express a human or chimeric (e.g., humanized) SIRP? and/or human or chimeric (e.g., humanized) CD47, and methods of use thereof.

Abstract: Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals expressing human or chimeric (e.g., humanized) Thrombopoietin (THPO), and methods of use thereof.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL10R and/or a human or chimeric (e.g., humanized) IL10, and methods of use thereof.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.